JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Riociguat (formerly also known as BAY 63-2521, and BAY 632521) is a novel, potent and oral bioavailable and soluble guanylate cyclase (GC) stimulator that is currently in clinical development. Riociguat is used in the treatment of ipulmonary hypertension. Riociguat is currently in clinical development by Bayer. The Phase III clinical trials investigated the use of riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of a novel class of sGC stimulators.
References: Eur Respir J. 2008 Oct; 32(4):881-91; Br J Pharmacol. 2015 Nov; 172(21):5199-210.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!